Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Wildtype”

117 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 117 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)UnknownNCT02967497
What this trial is testing

Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type

Who this might be right for
Epithelial Growth Factor Receptor Negative Non-small Cell Lung Cancer
Taipei Veterans General Hospital, Taiwan 56
Not applicableUnknownNCT05051592
What this trial is testing

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

Who this might be right for
Colorectal Cancer
National University Hospital, Singapore 40
Testing effectiveness (Phase 2)UnknownNCT03062800
What this trial is testing

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Who this might be right for
Advanced Nsclc
Qilu Hospital of Shandong University 232
Testing effectiveness (Phase 2)Looking for participantsNCT05777278
What this trial is testing

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Who this might be right for
Non-small Cell Lung Cancer
The First Affiliated Hospital of Guangzhou Medical University 29
Testing effectiveness (Phase 2)UnknownNCT01410214
What this trial is testing

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer Stage IIIA
Chinese Lung Cancer Surgical Group 80
Testing effectiveness (Phase 2)WithdrawnNCT02785068
What this trial is testing

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Merrimack Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Active Not RecruitingNCT05020457
What this trial is testing

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Who this might be right for
Non Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 69
Testing effectiveness (Phase 2)Looking for participantsNCT06568939
What this trial is testing

Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie 150
Testing effectiveness (Phase 2)UnknownNCT02631460
What this trial is testing

S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

Who this might be right for
NSCLC
Sun Yat-sen University 470
Testing effectiveness (Phase 2)Ended earlyNCT01374789
What this trial is testing

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer

Who this might be right for
Urinary Bladder Cancer
WiSP Wissenschaftlicher Service Pharma GmbH 2
Testing effectiveness (Phase 2)Looking for participantsNCT07724223
What this trial is testing

Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 46
Testing effectiveness (Phase 2)UnknownNCT02191059
What this trial is testing

Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Shandong Cancer Hospital and Institute 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT02493582
What this trial is testing

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Who this might be right for
Adenocarcinoma of Lung
The First People's Hospital of Changzhou 400
Testing effectiveness (Phase 2)Looking for participantsNCT06618287
What this trial is testing

Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Who this might be right for
Lung CancerBreast Cancer
Bristol-Myers Squibb 416
Testing effectiveness (Phase 2)WithdrawnNCT02876081
What this trial is testing

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex

Who this might be right for
SMALL CELL LUNG CARCINOMA
Fondation Hôpital Saint-Joseph
Testing effectiveness (Phase 2)UnknownNCT03992456
What this trial is testing

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Who this might be right for
Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Rectal Adenocarcinoma+27 more
Academic and Community Cancer Research United 12
Testing effectiveness (Phase 2)Study completedNCT00637091
What this trial is testing

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

Who this might be right for
Advanced Colorectal Cancer
Asan Medical Center 40
Large-scale testing (Phase 3)UnknownNCT02332512
What this trial is testing

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Jiangsu HengRui Medicine Co., Ltd. 417
Next Page